Isabel Heidegger

9PUBLICATIONS
26CO-AUTHORS
Predictive and prognostic markersMedical biotechnology diagnostics (incl. biosensors)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Mar 04, 2026
Real-world monitoring strategies and predictors guiding the transition from active surveillance to treatment in ISUP 1 prostate cancer.

Giulia Giannini, Amer Mousa, Eberhard Steiner

|Oct 24, 2025
MicroRNA-371a-3p Represents a Novel and Effective Diagnostic Marker for Testicular Germ Cell Tumours: A Real-World Prospective Comparison with Conventional Approaches.

Margherita Palermo, Carolina D'Elia, Giovanni Mazzucato

|Jan 25, 2025
Information Behaviour and Knowledge of Patients Before Radical Prostatectomy.

Christopher Hirtsiefer, Anna Vogelgesang, Fabian Falkenbach

|Nov 28, 2023
Glucocorticoid treatment influences prostate cancer cell growth and the tumor microenvironment via altered glucocorticoid receptor signaling in prostate fibroblasts.

Andrea Eigentler, Florian Handle, Silvia Schanung

|Feb 25, 2023
Mass Spectrometry-Based Biomarkers to Detect Prostate Cancer: A Multicentric Study Based on Non-Invasive Urine Collection without Prior Digital Rectal Examination.

Maria Frantzi, Zoran Culig, Isabel Heidegger

|Oct 26, 2022
Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response.

Mona Kafka, Thomas Burtscher, Josef Fritz

Pageof 2

Frequent Collaborators

2 joint publications

Cristian Mirvald

2 joint publications

Igor Tsaur

1 joint publications

Alexander Kretschmer

1 joint publications

Maria Frantzi